XBiotech Inc (XBIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XBiotech Inc (XBIT) has a cash flow conversion efficiency ratio of -0.164x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.95 Million) by net assets ($140.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XBIT stock market capitalisation for the company's overall valuation and market capitalisation.
XBiotech Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how XBiotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
XBiotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XBiotech Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of XBiotech Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quality Houses Hotel and Residence Freehold and Leasehold Property Fund
BK:QHHR
|
0.017x |
|
Apex Science & Engineering Corp
TW:3052
|
0.515x |
|
Camus Engineering & Construction Inc
KO:013700
|
0.207x |
|
Decidr Ai Industries Ltd
AU:DAI
|
-0.079x |
|
BitNine Co. Ltd.
KQ:357880
|
-0.072x |
|
Interlink Electronics Inc
NASDAQ:LINK
|
0.068x |
|
Cypherpunk Technologies Inc.
NASDAQ:CYPH
|
-0.041x |
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
0.135x |
Annual Cash Flow Conversion Efficiency for XBiotech Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of XBiotech Inc from 2012 to 2025. View latest XBiotech Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $140.35 Million | $-39.92 Million | -0.284x | -67.43% |
| 2024-12-31 | $182.27 Million | $-30.96 Million | -0.170x | -98.54% |
| 2023-12-31 | $218.85 Million | $-18.73 Million | -0.086x | -38.76% |
| 2022-12-31 | $240.40 Million | $-14.82 Million | -0.062x | -123.92% |
| 2021-12-31 | $269.38 Million | $69.44 Million | 0.258x | +237.95% |
| 2020-12-31 | $348.64 Million | $-65.15 Million | -0.187x | -672.86% |
| 2019-12-31 | $755.63 Million | $-18.27 Million | -0.024x | +93.95% |
| 2018-12-31 | $41.40 Million | $-16.54 Million | -0.399x | +28.58% |
| 2017-12-31 | $60.16 Million | $-33.65 Million | -0.559x | +28.21% |
| 2016-12-31 | $59.06 Million | $-46.02 Million | -0.779x | -141.03% |
| 2015-12-31 | $103.05 Million | $-33.31 Million | -0.323x | -63.08% |
| 2014-12-31 | $59.03 Million | $-11.70 Million | -0.198x | +77.24% |
| 2013-12-31 | $10.23 Million | $-8.91 Million | -0.871x | +44.81% |
| 2012-12-31 | $7.37 Million | $-11.63 Million | -1.578x | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more